Protocols
11 protocol(s) meet the specified criteria
PI: Weiss, Jared
Protocol No.TitleStatus
8273-CL-0102An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsOpen
B1641004A Phase 1B Study of PF-05082566 in Combination with Mogamulizumab (KW-0761) in Patients with Advanced Solid TumorsOpen
CALGB30607Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer Open (affiliates only)
G1T28-02Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin ChemotherapyOpen
LCCC1123Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI Open
LCCC1210Tolerability of weekly nab-paclitaxel as second line treatment for elderly patients with advanced lung cancerOpen
LCCC1330A Phase II study of carboplatin, paclitaxel and cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neckOpen
LCCC1509Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) not Eligible for Cisplatin TherapyOpen
LCCC1516A Randomized, Non-comparative Three Arm Phase II Trial of Sequential Consolidation with Pembrolizumab followed by Nab-paclitaxel, Sequential Consolidation with Nab-paclitaxel followed by Pembrolizumab and Concurrent Consolidation with Nab-paclitaxel and Pembrolizumab after Standard First-Line Induction Chemotherapy in Advanced NSCLCOpen
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
RC1126Randomized Phase II Trial of Erlotinib Alone or In Combination with Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor MutationsOpen